Journal of Clinical Medicine

Research

22 pages, 608 KiB

Open AccessArticle

Scalable Electrophysiological Investigation of iPS Cell-Derived Cardiomyocytes Obtained by a Lentiviral Purification Strategy

by Stephanie Friedrichs, Daniela Malan, Yvonne Voss and Philipp Sasse

J. Clin. Med. 2015, 4(1), 102-123; https://doi.org/10.3390/jcm4010102 - 8 Jan 2015

Cited by 13 | Viewed by 11088

Abstract

Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and differentiated into functional cardiomyocytes for characterization of the disease and for drug screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, we here report a novel non-clonal purification strategy [...] Read more.

Disease-specific induced pluripotent stem (iPS) cells can be generated from patients and differentiated into functional cardiomyocytes for characterization of the disease and for drug screening. In order to obtain pure cardiomyocytes for automated electrophysiological investigation, we here report a novel non-clonal purification strategy by using lentiviral gene transfer of a puromycin resistance gene under the control of a cardiac-specific promoter. We have applied this method to our previous reported wild-type and long QT syndrome 3 (LQTS 3)-specific mouse iPS cells and obtained a pure cardiomyocyte population. These cells were investigated by action potential analysis with manual and automatic planar patch clamp technologies, as well as by recording extracellular field potentials using a microelectrode array system. Action potentials and field potentials showed the characteristic prolongation at low heart rates in LQTS 3-specific, but not in wild-type iPS cell-derived cardiomyocytes. Hence, LQTS 3-specific cardiomyocytes can be purified from iPS cells with a lentiviral strategy, maintain the hallmarks of the LQTS 3 disease and can be used for automated electrophysiological characterization and drug screening. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

Review

Jump to: Research, Other

14 pages, 121 KiB

Open AccessReview

The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases

by Meilyn Hew, Kevin O'Connor, Michael J. Edel and Michaela Lucas

J. Clin. Med. 2015, 4(6), 1193-1206; https://doi.org/10.3390/jcm4061193 - 28 May 2015

Cited by 13 | Viewed by 6459

Abstract

The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and [...] Read more.

The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

14 pages, 162 KiB

Open AccessReview

Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease

by Alexis Bosman, Michael J. Edel, Gillian Blue, Rodney J. Dilley, Richard P. Harvey and David S. Winlaw

J. Clin. Med. 2015, 4(4), 768-781; https://doi.org/10.3390/jcm4040768 - 22 Apr 2015

Cited by 3 | Viewed by 7115

Abstract

Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve [...] Read more.

Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve both structural and functional aspects of disease. Stem cell therapy has demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. This finding, together with promising case studies in the paediatric setting, demonstrates the potential for this treatment in congenital heart disease. Furthermore, induced pluripotent stems cell technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects of disease. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

19 pages, 316 KiB

Open AccessReview

Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells

by Youssef Hibaoui and Anis Feki

J. Clin. Med. 2015, 4(4), 696-714; https://doi.org/10.3390/jcm4040696 - 15 Apr 2015

Cited by 8 | Viewed by 8579

Abstract

Down syndrome (DS, trisomy 21), is the most common viable chromosomal disorder, with an incidence of 1 in 800 live births. Its phenotypic characteristics include intellectual impairment and several other developmental abnormalities, for the majority of which the pathogenetic mechanisms remain unknown. Several [...] Read more.

Down syndrome (DS, trisomy 21), is the most common viable chromosomal disorder, with an incidence of 1 in 800 live births. Its phenotypic characteristics include intellectual impairment and several other developmental abnormalities, for the majority of which the pathogenetic mechanisms remain unknown. Several models have been used to investigate the mechanisms by which the extra copy of chromosome 21 leads to the DS phenotype. In the last five years, several laboratories have been successful in reprogramming patient cells carrying the trisomy 21 anomaly into induced pluripotent stem cells, i.e., T21-iPSCs. In this review, we summarize the different T21-iPSCs that have been generated with a particular interest in the technical procedures and the somatic cell types used for the reprogramming. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

12 pages, 61 KiB

Open AccessReview

Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases

by Huy V. Nguyen, Yao Li and Stephen H. Tsang

J. Clin. Med. 2015, 4(4), 567-578; https://doi.org/10.3390/jcm4040567 - 31 Mar 2015

Cited by 27 | Viewed by 7969

Abstract

Inherited retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, are the leading cause of blindness in the developed world. Currently, treatments for these conditions are limited. Recently, considerable attention has been given to the possibility of using patient-specific induced pluripotent stem [...] Read more.

Inherited retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, are the leading cause of blindness in the developed world. Currently, treatments for these conditions are limited. Recently, considerable attention has been given to the possibility of using patient-specific induced pluripotent stem cells (iPSCs) as a treatment for these conditions. iPSCs reprogrammed from adult somatic cells offer the possibility of generating patient-specific cell lines in vitro. In this review, we will discuss the current literature pertaining to iPSC modeling of retinal disease, gene therapy of iPSC-derived retinal pigmented epithelium (RPE) cells, and retinal transplantation. We will focus on the use of iPSCs created from patients with inherited eye diseases for testing the efficacy of gene or drug-based therapies, elucidating previously unknown mechanisms and pathways of disease, and as a source of autologous cells for cell replacement. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

19 pages, 285 KiB

Open AccessReview

Using iPS Cells toward the Understanding of Parkinson’s Disease

by Roger Torrent, Francesca De Angelis Rigotti, Patrizia Dell'Era, Maurizio Memo, Angel Raya and Antonella Consiglio

J. Clin. Med. 2015, 4(4), 548-566; https://doi.org/10.3390/jcm4040548 - 30 Mar 2015

Cited by 46 | Viewed by 13927

Abstract

Cellular reprogramming of somatic cells to human pluripotent stem cells (iPSC) represents an efficient tool for in vitro modeling of human brain diseases and provides an innovative opportunity in the identification of new therapeutic drugs. Patient-specific iPSC can be differentiated into disease-relevant cell [...] Read more.

Cellular reprogramming of somatic cells to human pluripotent stem cells (iPSC) represents an efficient tool for in vitro modeling of human brain diseases and provides an innovative opportunity in the identification of new therapeutic drugs. Patient-specific iPSC can be differentiated into disease-relevant cell types, including neurons, carrying the genetic background of the donor and enabling de novo generation of human models of genetically complex disorders. Parkinson’s disease (PD) is the second most common age-related progressive neurodegenerative disease, which is mainly characterized by nigrostriatal dopaminergic (DA) neuron degeneration and synaptic dysfunction. Recently, the generation of disease-specific iPSC from patients suffering from PD has unveiled a recapitulation of disease-related cell phenotypes, such as abnormal α-synuclein accumulation and alterations in autophagy machinery. The use of patient-specific iPSC has a remarkable potential to uncover novel insights of the disease pathogenesis, which in turn will open new avenues for clinical intervention. This review explores the current Parkinson’s disease iPSC-based models highlighting their role in the discovery of new drugs, as well as discussing the most challenging limitations iPSC-models face today. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

25 pages, 248 KiB

Open AccessReview

Potential Role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular Surface

by Ricardo P. Casaroli-Marano, Núria Nieto-Nicolau, Eva M. Martínez-Conesa, Michael Edel and Ana B.Álvarez-Palomo

J. Clin. Med. 2015, 4(2), 318-342; https://doi.org/10.3390/jcm4020318 - 12 Feb 2015

Cited by 23 | Viewed by 10094

Abstract

The integrity and normal function of the corneal epithelium are crucial for maintaining the cornea’s transparency and vision. The existence of a cell population with progenitor characteristics in the limbus maintains a dynamic of constant epithelial repair and renewal. Currently, cell-based therapies for [...] Read more.

The integrity and normal function of the corneal epithelium are crucial for maintaining the cornea’s transparency and vision. The existence of a cell population with progenitor characteristics in the limbus maintains a dynamic of constant epithelial repair and renewal. Currently, cell-based therapies for bio replacement—cultured limbal epithelial transplantation (CLET) and cultured oral mucosal epithelial transplantation (COMET)—present very encouraging clinical results for treating limbal stem cell deficiency (LSCD) and restoring vision. Another emerging therapeutic approach consists of obtaining and implementing human progenitor cells of different origins in association with tissue engineering methods. The development of cell-based therapies using stem cells, such as human adult mesenchymal or induced pluripotent stem cells (IPSCs), represent a significant breakthrough in the treatment of certain eye diseases, offering a more rational, less invasive, and better physiological treatment option in regenerative medicine for the ocular surface. This review will focus on the main concepts of cell-based therapies for the ocular surface and the future use of IPSCs to treat LSCD. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

17 pages, 148 KiB

Open AccessReview

Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy

by Isart Roca, Jordi Requena, Michael J. Edel and Ana Belén Alvarez-Palomo

J. Clin. Med. 2015, 4(2), 243-259; https://doi.org/10.3390/jcm4020243 - 29 Jan 2015

Cited by 26 | Viewed by 8083

Abstract

The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate [...] Read more.

The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

13 pages, 331 KiB

Open AccessReview

Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products

by Shin Kawamata, Hoshimi Kanemura, Noriko Sakai, Masayo Takahashi and Masahiro J. Go

J. Clin. Med. 2015, 4(1), 159-171; https://doi.org/10.3390/jcm4010159 - 14 Jan 2015

Cited by 59 | Viewed by 11611

Abstract

Human Pluripotent Stem Cell (PSC)-derived cell therapy holds enormous promise because of the cells’ “unlimited” proliferative capacity and the potential to differentiate into any type of cell. However, these features of PSC-derived cell products are associated with concerns regarding the generation of iatrogenic [...] Read more.

Human Pluripotent Stem Cell (PSC)-derived cell therapy holds enormous promise because of the cells’ “unlimited” proliferative capacity and the potential to differentiate into any type of cell. However, these features of PSC-derived cell products are associated with concerns regarding the generation of iatrogenic teratomas or tumors from residual immature or non-terminally differentiated cells in the final cell product. This concern has become a major hurdle to the introduction of this therapy into the clinic. Tumorigenicity testing is therefore a key preclinical safety test in PSC-derived cell therapy. Tumorigenicity testing becomes particularly important when autologous human induced Pluripotent Stem Cell (iPSC)-derived cell products with no immuno-barrier are considered for transplantation. There has been, however, no internationally recognized guideline for tumorigenicity testing of PSC-derived cell products for cell therapy. In this review, we outline the points to be considered in the design and execution of tumorigenicity tests, referring to the tests and laboratory work that we have conducted for an iPSC-derived retinal pigment epithelium (RPE) cell product prior to its clinical use. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

29 pages, 660 KiB

Open AccessReview

The Potential for iPS-Derived Stem Cells as a Therapeutic Strategy for Spinal Cord Injury: Opportunities and Challenges

by Mohamad Khazaei, Ahad M. Siddiqui and Michael G. Fehlings

J. Clin. Med. 2015, 4(1), 37-65; https://doi.org/10.3390/jcm4010037 - 29 Dec 2014

Cited by 27 | Viewed by 11916

Abstract

Spinal cord injury (SCI) is a devastating trauma causing long-lasting disability. Although advances have occurred in the last decade in the medical, surgical and rehabilitative treatments of SCI, the therapeutic approaches are still not ideal. The use of cell transplantation as a therapeutic [...] Read more.

Spinal cord injury (SCI) is a devastating trauma causing long-lasting disability. Although advances have occurred in the last decade in the medical, surgical and rehabilitative treatments of SCI, the therapeutic approaches are still not ideal. The use of cell transplantation as a therapeutic strategy for the treatment of SCI is promising, particularly since it can target cell replacement, neuroprotection and regeneration. Cell therapies for treating SCI are limited due to several translational roadblocks, including ethical and practical concerns regarding cell sources. The use of iPSCs has been particularly attractive, since they avoid the ethical and moral concerns that surround other stem cells. Furthermore, various cell types with potential for application in the treatment of SCI can be created from autologous sources using iPSCs. For applications in SCI, the iPSCs can be differentiated into neural precursor cells, neurons, oligodendrocytes, astrocytes, neural crest cells and mesenchymal stromal cells that can act by replacing lost cells or providing environmental support. Some methods, such as direct reprogramming, are being investigated to reduce tumorigenicity and improve reprogramming efficiencies, which have been some of the issues surrounding the use of iPSCs clinically to date. Recently, iPSCs have entered clinical trials for use in age-related macular degeneration, further supporting their promise for translation in other conditions, including SCI. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

31 pages, 2391 KiB

Open AccessReview

iPS Cells for Modelling and Treatment of Retinal Diseases

by Fred K. Chen, Samuel McLenachan, Michael Edel, Lyndon Da Cruz, Peter J. Coffey and David A. Mackey

J. Clin. Med. 2014, 3(4), 1511-1541; https://doi.org/10.3390/jcm3041511 - 19 Dec 2014

Cited by 16 | Viewed by 10371

Abstract

For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of [...] Read more.

For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

21 pages, 282 KiB

Open AccessReview

The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders

by I-Ping Chen

J. Clin. Med. 2014, 3(4), 1490-1510; https://doi.org/10.3390/jcm3041490 - 17 Dec 2014

Cited by 9 | Viewed by 8421

Abstract

More than 500 rare genetic bone disorders have been described, but for many of them only limited treatment options are available. Challenges for studying these bone diseases come from a lack of suitable animal models and unavailability of skeletal tissues for studies. Effectors [...] Read more.

More than 500 rare genetic bone disorders have been described, but for many of them only limited treatment options are available. Challenges for studying these bone diseases come from a lack of suitable animal models and unavailability of skeletal tissues for studies. Effectors for skeletal abnormalities of bone disorders may be abnormal bone formation directed by osteoblasts or anomalous bone resorption by osteoclasts, or both. Patient-specific induced pluripotent stem cells (iPSCs) can be generated from somatic cells of various tissue sources and in theory can be differentiated into any desired cell type. However, successful differentiation of hiPSCs into functional bone cells is still a challenge. Our group focuses on the use of human iPSCs (hiPSCs) to identify osteoclast defects in craniometaphyseal dysplasia. In this review, we describe the impact of stem cell technology on research for better treatment of such disorders, the generation of hiPSCs from patients with rare genetic bone disorders and current protocols for differentiating hiPSCs into osteoclasts. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

35 pages, 522 KiB

Open AccessReview

Induced Pluripotent Stem Cells Derived from Alzheimer’s Disease Patients: The Promise, the Hope and the Path Ahead

by Kristine Freude, Carlota Pires, Poul Hyttel and Vanessa Jane Hall

J. Clin. Med. 2014, 3(4), 1402-1436; https://doi.org/10.3390/jcm3041402 - 12 Dec 2014

Cited by 14 | Viewed by 15251

Abstract

The future hope of generated induced pluripotent stem cells (iPS cells) from Alzheimer’s disease patients is multifold. Firstly, they may help to uncover novel mechanisms of the disease, which could lead to the development of new and unprecedented drugs for patients and secondly, [...] Read more.

The future hope of generated induced pluripotent stem cells (iPS cells) from Alzheimer’s disease patients is multifold. Firstly, they may help to uncover novel mechanisms of the disease, which could lead to the development of new and unprecedented drugs for patients and secondly, they could also be directly used for screening and testing of potential new compounds for drug discovery. In addition, in the case of familial known mutations, these cells could be targeted by use of advanced gene-editing techniques to correct the mutation and be used for future cell transplantation therapies. This review summarizes the work so far in regards to production and characterization of iPS cell lines from both sporadic and familial Alzheimer’s patients and from other iPS cell lines that may help to model the disease. It provides a detailed comparison between published reports and states the present hurdles we face with this new technology. The promise of new gene-editing techniques and accelerated aging models also aim to move this field further by providing better control cell lines for comparisons and potentially better phenotypes, respectively. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

16 pages, 350 KiB

Open AccessReview

Opportunities and Limitations of Modelling Alzheimer’s Disease with Induced Pluripotent Stem Cells

by Dmitry A. Ovchinnikov and Ernst J. Wolvetang

J. Clin. Med. 2014, 3(4), 1357-1372; https://doi.org/10.3390/jcm3041357 - 5 Dec 2014

Cited by 12 | Viewed by 10636

Abstract

Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has opened the way for patient-specific disease modelling. Following their differentiation into neuronal cell types, iPSC have enabled the investigation of human neurodegenerative diseases, such as Alzheimer’s disease (AD). While human iPSCs certainly [...] Read more.

Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has opened the way for patient-specific disease modelling. Following their differentiation into neuronal cell types, iPSC have enabled the investigation of human neurodegenerative diseases, such as Alzheimer’s disease (AD). While human iPSCs certainly provide great opportunities to repeatedly interrogate specific human brain cell types of individuals with familial and sporadic forms of the disease, the complex aetiology and timescale over which AD develops in humans poses particular challenges to iPSC-based AD models. Here, we discuss the current state-of-play in the context of these and other iPSC model-related challenges and elaborate on likely future developments in this field of research. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

17 pages, 1255 KiB

Open AccessReview

Comparing ESC and iPSC—Based Models for Human Genetic Disorders

by Tomer Halevy and Achia Urbach

J. Clin. Med. 2014, 3(4), 1146-1162; https://doi.org/10.3390/jcm3041146 - 24 Oct 2014

Cited by 59 | Viewed by 14240

Abstract

Traditionally, human disorders were studied using animal models or somatic cells taken from patients. Such studies enabled the analysis of the molecular mechanisms of numerous disorders, and led to the discovery of new treatments. Yet, these systems are limited or even irrelevant in [...] Read more.

Traditionally, human disorders were studied using animal models or somatic cells taken from patients. Such studies enabled the analysis of the molecular mechanisms of numerous disorders, and led to the discovery of new treatments. Yet, these systems are limited or even irrelevant in modeling multiple genetic diseases. The isolation of human embryonic stem cells (ESCs) from diseased blastocysts, the derivation of induced pluripotent stem cells (iPSCs) from patients’ somatic cells, and the new technologies for genome editing of pluripotent stem cells have opened a new window of opportunities in the field of disease modeling, and enabled studying diseases that couldn’t be modeled in the past. Importantly, despite the high similarity between ESCs and iPSCs, there are several fundamental differences between these cells, which have important implications regarding disease modeling. In this review we compare ESC-based models to iPSC-based models, and highlight the advantages and disadvantages of each system. We further suggest a roadmap for how to choose the optimal strategy to model each specific disorder. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Figure 1

22 pages, 1386 KiB

Open AccessReview

iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development

by Irene Faravelli, Emanuele Frattini, Agnese Ramirez, Giulia Stuppia, Monica Nizzardo and Stefania Corti

J. Clin. Med. 2014, 3(4), 1124-1145; https://doi.org/10.3390/jcm3041124 - 17 Oct 2014

Cited by 5 | Viewed by 9401

Abstract

Motor neuron diseases (MNDs) are neuromuscular disorders affecting rather exclusively upper motor neurons (UMNs) and/or lower motor neurons (LMNs). The clinical phenotype is characterized by muscular weakness and atrophy leading to paralysis and almost invariably death due to respiratory failure. Adult MNDs include [...] Read more.

Motor neuron diseases (MNDs) are neuromuscular disorders affecting rather exclusively upper motor neurons (UMNs) and/or lower motor neurons (LMNs). The clinical phenotype is characterized by muscular weakness and atrophy leading to paralysis and almost invariably death due to respiratory failure. Adult MNDs include sporadic and familial amyotrophic lateral sclerosis (sALS-fALS), while the most common infantile MND is represented by spinal muscular atrophy (SMA). No effective treatment is ccurrently available for MNDs, as for the vast majority of neurodegenerative disorders, and cures are limited to supportive care and symptom relief. The lack of a deep understanding of MND pathogenesis accounts for the difficulties in finding a cure, together with the scarcity of reliable in vitro models. Recent progresses in stem cell field, in particular in the generation of induced Pluripotent Stem Cells (iPSCs) has made possible for the first time obtaining substantial amounts of human cells to recapitulate in vitro some of the key pathogenetic processes underlying MNDs. In the present review, recently published studies involving the use of iPSCs to unravel aspects of ALS and SMA pathogenesis are discussed with an overview of their implications in the process of finding a cure for these still orphan disorders. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

19 pages, 972 KiB

Open AccessReview

Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells

by Kwong-Man Ng, Cheuk-Yiu Law and Hung-Fat Tse

J. Clin. Med. 2014, 3(4), 1105-1123; https://doi.org/10.3390/jcm3041105 - 15 Oct 2014

Cited by 1 | Viewed by 7368

Abstract

The lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into [...] Read more.

The lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

20 pages, 1088 KiB

Open AccessReview

Human iPS Cell-Derived Germ Cells: Current Status and Clinical Potential

by Tetsuya Ishii

J. Clin. Med. 2014, 3(4), 1064-1083; https://doi.org/10.3390/jcm3041064 - 13 Oct 2014

Cited by 21 | Viewed by 15552

Abstract

Recently, fertile spermatozoa and oocytes were generated from mouse induced pluripotent (iPS) cells using a combined in vitro and in vivo induction system. With regard to germ cell induction from human iPS cells, progress has been made particularly in the male germline, demonstrating [...] Read more.

Recently, fertile spermatozoa and oocytes were generated from mouse induced pluripotent (iPS) cells using a combined in vitro and in vivo induction system. With regard to germ cell induction from human iPS cells, progress has been made particularly in the male germline, demonstrating in vitro generation of haploid, round spermatids. Although iPS-derived germ cells are expected to be developed to yield a form of assisted reproductive technology (ART) that can address unmet reproductive needs, genetic and/or epigenetic instabilities abound in iPS cell generation and germ cell induction. In addition, there is still room to improve the induction protocol in the female germline. However, rapid advances in stem cell research are likely to make such obstacles surmountable, potentially translating induced germ cells into the clinical setting in the immediate future. This review examines the current status of the induction of germ cells from human iPS cells and discusses the clinical potential, as well as future directions. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

► Show Figures

Graphical abstract

21 pages, 752 KiB

Open AccessReview

Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment

by Yue Yu, Xuehao Wang and Scott L. Nyberg

J. Clin. Med. 2014, 3(3), 997-1017; https://doi.org/10.3390/jcm3030997 - 5 Sep 2014

Cited by 26 | Viewed by 7791

Abstract

Tens of millions of patients are affected by liver disease worldwide. Many of these patients can benefit from cell therapy involving living metabolically active cells, either by treatment of their liver disease, or by prevention of their disease phenotype. Cell therapies, including hepatocyte [...] Read more.

Tens of millions of patients are affected by liver disease worldwide. Many of these patients can benefit from cell therapy involving living metabolically active cells, either by treatment of their liver disease, or by prevention of their disease phenotype. Cell therapies, including hepatocyte transplantation and bioartificial liver (BAL) devices, have been proposed as therapeutic alternatives to the shortage of transplantable livers. Both BAL and hepatocyte transplantation are cellular therapies that avoid use of a whole liver. Hepatocytes are also widely used in drug screening and liver disease modelling. However, the demand for human hepatocytes, heavily outweighs their availability by conventional means. Induced pluripotent stem cells (iPSCs) technology brings together the potential benefits of embryonic stem cells (ESCs) (i.e., self-renewal, pluripotency) and addresses the major ethical and scientific concerns of ESCs: embryo destruction and immune-incompatibility. It has been shown that hepatocyte-like cells (HLCs) can be generated from iPSCs. Furthermore, human iPSCs (hiPSCs) can provide an unlimited source of human hepatocytes and hold great promise for applications in regenerative medicine, drug screening and liver diseases modelling. Despite steady progress, there are still several major obstacles that need to be overcome before iPSCs will reach the bedside. This review will focus on the current state of efforts to derive hiPSCs for potential use in modelling and treatment of liver disease. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

Other

Jump to: Research, Review

11 pages, 59 KiB

Open AccessCommentary

The State of Play with iPSCs and Spinal Cord Injury Models

by Stuart I. Hodgetts, Michael Edel and Alan R. Harvey

J. Clin. Med. 2015, 4(1), 193-203; https://doi.org/10.3390/jcm4010193 - 14 Jan 2015

Cited by 7 | Viewed by 6527

Abstract

The application of induced pluripotent stem cell (iPSC) technologies in cell based strategies, for the repair of the central nervous system (with particular focus on the spinal cord), is moving towards the potential use of clinical grade donor cells. The ability of iPSCs [...] Read more.

The application of induced pluripotent stem cell (iPSC) technologies in cell based strategies, for the repair of the central nervous system (with particular focus on the spinal cord), is moving towards the potential use of clinical grade donor cells. The ability of iPSCs to generate donor neuronal, glial and astrocytic phenotypes for transplantation is highlighted here, and we review recent research using iPSCs in attempts to treat spinal cord injury in various animal models. Also discussed are issues relating to the production of clinical grade iPSCs, recent advances in transdifferentiation protocols for iPSC-derived donor cell populations, concerns about tumourogenicity, and whether iPSC technologies offer any advantages over previous donor cell candidates or tissues already in use as therapeutic tools in experimental spinal cord injury studies. Full article

(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)

Journal Menu

Journal Browser

iPS Cells for Modelling and Treatment of Human Diseases

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (20 papers)

Research

Review

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI